C WorldWide Group Holding A S acquired a new stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 267,012 shares of the biopharmaceutical company’s stock, valued at approximately $14,878,000.
Other large investors also recently made changes to their positions in the company. Tradewinds Capital Management LLC raised its stake in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the last quarter. Welch Investments LLC raised its stake in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the last quarter. Blue Chip Partners Inc. raised its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the last quarter. American National Bank raised its stake in Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its stake in Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares during the last quarter. Institutional investors and hedge funds own 68.84% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 64.42 on Friday. The company has a 50 day moving average price of $63.37 and a 200 day moving average price of $57.29. The company has a market cap of $105.64 billion, a price-to-earnings ratio of 23.53 and a beta of 1.19. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. Equities analysts predict that Bristol-Myers Squibb Company will post $2.99 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
In related news, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
A number of analysts have commented on the company. Hilliard Lyons lowered Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Jefferies Group LLC lifted their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies set a $60.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets reissued a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $63.79.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.